Opioid binding properties of the purified kappa receptor from human placenta

Mahmoud Ahmed, De he Zhou, Anna G. Cavinato, Dev Maulik

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

A glycoprotein with a molecular weight of 63,000 has been purified, in an active form, from human placental villus tissue membranes. The binding properties of this glycoprotein to opioid alkaloids and peptides indicates that it is the kappa opiate receptor of human placenta. The receptor binds the tritiated ligands etorphine, bremazocine, ethylketocyclazocine and naloxone specifically and reversibly with Kd values of 3.3, 4.4, 5.1 and 7.0nM, respectively. The binding of 3H-Bremazocine to the purified receptor is inhibited by the following compounds with the corresponding Ki values EKC, 1.3×10-8M; Dynorphin 1-8, 3.03×10-7; U50,488H, 4.48×10-9; U69-593, 2.28×10-8, morphine, 4.05×10-6 DADLE, 6.47×10-6 and naloxone, 2.64×10-8. The purified receptor binds 8 nmole of 3H-Etorphine and 1.7 nmole 3H-BZC per mg protein. The theoretical binding capacity of a protein of this molecular weight is 15.8. Although the iodinated purified receptor appears by autoradiography as one band on SDS-PAGE, yet homogeneity of the preparation is not claimed.

Original languageEnglish (US)
Pages (from-to)861-871
Number of pages11
JournalLife Sciences
Volume44
Issue number13
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Etorphine
kappa Opioid Receptor
dynorphin (1-8)
Naloxone
Placenta
Opioid Analgesics
Glycoproteins
Leucine-2-Alanine Enkephalin
Ethylketocyclazocine
Molecular Weight
Molecular weight
Chorionic Villi
Opioid Peptides
Opioid Receptors
Autoradiography
Alkaloids
Morphine
Polyacrylamide Gel Electrophoresis
Proteins
Tissue

ASJC Scopus subject areas

  • Pharmacology

Cite this

Opioid binding properties of the purified kappa receptor from human placenta. / Ahmed, Mahmoud; Zhou, De he; Cavinato, Anna G.; Maulik, Dev.

In: Life Sciences, Vol. 44, No. 13, 1989, p. 861-871.

Research output: Contribution to journalArticle

Ahmed, Mahmoud ; Zhou, De he ; Cavinato, Anna G. ; Maulik, Dev. / Opioid binding properties of the purified kappa receptor from human placenta. In: Life Sciences. 1989 ; Vol. 44, No. 13. pp. 861-871.
@article{f24b102ec6864a6a8c0399c217b87ed7,
title = "Opioid binding properties of the purified kappa receptor from human placenta",
abstract = "A glycoprotein with a molecular weight of 63,000 has been purified, in an active form, from human placental villus tissue membranes. The binding properties of this glycoprotein to opioid alkaloids and peptides indicates that it is the kappa opiate receptor of human placenta. The receptor binds the tritiated ligands etorphine, bremazocine, ethylketocyclazocine and naloxone specifically and reversibly with Kd values of 3.3, 4.4, 5.1 and 7.0nM, respectively. The binding of 3H-Bremazocine to the purified receptor is inhibited by the following compounds with the corresponding Ki values EKC, 1.3×10-8M; Dynorphin 1-8, 3.03×10-7; U50,488H, 4.48×10-9; U69-593, 2.28×10-8, morphine, 4.05×10-6 DADLE, 6.47×10-6 and naloxone, 2.64×10-8. The purified receptor binds 8 nmole of 3H-Etorphine and 1.7 nmole 3H-BZC per mg protein. The theoretical binding capacity of a protein of this molecular weight is 15.8. Although the iodinated purified receptor appears by autoradiography as one band on SDS-PAGE, yet homogeneity of the preparation is not claimed.",
author = "Mahmoud Ahmed and Zhou, {De he} and Cavinato, {Anna G.} and Dev Maulik",
year = "1989",
doi = "10.1016/0024-3205(89)90586-9",
language = "English (US)",
volume = "44",
pages = "861--871",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "13",

}

TY - JOUR

T1 - Opioid binding properties of the purified kappa receptor from human placenta

AU - Ahmed, Mahmoud

AU - Zhou, De he

AU - Cavinato, Anna G.

AU - Maulik, Dev

PY - 1989

Y1 - 1989

N2 - A glycoprotein with a molecular weight of 63,000 has been purified, in an active form, from human placental villus tissue membranes. The binding properties of this glycoprotein to opioid alkaloids and peptides indicates that it is the kappa opiate receptor of human placenta. The receptor binds the tritiated ligands etorphine, bremazocine, ethylketocyclazocine and naloxone specifically and reversibly with Kd values of 3.3, 4.4, 5.1 and 7.0nM, respectively. The binding of 3H-Bremazocine to the purified receptor is inhibited by the following compounds with the corresponding Ki values EKC, 1.3×10-8M; Dynorphin 1-8, 3.03×10-7; U50,488H, 4.48×10-9; U69-593, 2.28×10-8, morphine, 4.05×10-6 DADLE, 6.47×10-6 and naloxone, 2.64×10-8. The purified receptor binds 8 nmole of 3H-Etorphine and 1.7 nmole 3H-BZC per mg protein. The theoretical binding capacity of a protein of this molecular weight is 15.8. Although the iodinated purified receptor appears by autoradiography as one band on SDS-PAGE, yet homogeneity of the preparation is not claimed.

AB - A glycoprotein with a molecular weight of 63,000 has been purified, in an active form, from human placental villus tissue membranes. The binding properties of this glycoprotein to opioid alkaloids and peptides indicates that it is the kappa opiate receptor of human placenta. The receptor binds the tritiated ligands etorphine, bremazocine, ethylketocyclazocine and naloxone specifically and reversibly with Kd values of 3.3, 4.4, 5.1 and 7.0nM, respectively. The binding of 3H-Bremazocine to the purified receptor is inhibited by the following compounds with the corresponding Ki values EKC, 1.3×10-8M; Dynorphin 1-8, 3.03×10-7; U50,488H, 4.48×10-9; U69-593, 2.28×10-8, morphine, 4.05×10-6 DADLE, 6.47×10-6 and naloxone, 2.64×10-8. The purified receptor binds 8 nmole of 3H-Etorphine and 1.7 nmole 3H-BZC per mg protein. The theoretical binding capacity of a protein of this molecular weight is 15.8. Although the iodinated purified receptor appears by autoradiography as one band on SDS-PAGE, yet homogeneity of the preparation is not claimed.

UR - http://www.scopus.com/inward/record.url?scp=0024520722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024520722&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(89)90586-9

DO - 10.1016/0024-3205(89)90586-9

M3 - Article

C2 - 2538693

AN - SCOPUS:0024520722

VL - 44

SP - 861

EP - 871

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 13

ER -